quinazolines has been researched along with Androgen-Independent Prostatic Cancer in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, L; Cao, Q; Chen, K; Huang, X; Li, X; Liu, L; Lou, N; Qiu, B; Ruan, H; Wang, K; Xiao, W; Xu, G; Yang, H; Yuan, C; Zhang, X | 1 |
| Al-Janadi, A; Bolton, S; Flaig, T; Heath, E; Heilbrun, L; Hussain, A; Ivy, SP; Lara, P; Liu, G; Mack, P; Mannuel, H; Monk, JP; Silbiger, D; Smith, D; Stella, P; Usman, M; Vaishampayan, U; Zurita, A | 1 |
| Bloomfield, D; de Bono, JS; Fong, PC; Heath, C; Hickish, T; Jenkins, P; Jones, RJ; Karavasilis, V; Lumsden, G; Molife, LR; O'Sullivan, JM; Olmos, D; Omlin, A; Oommen, N; Pedley, I; Pelling, K; Temple, G; Thompson, E; Wheatley, D | 1 |
| Azad, AA; Beardsley, EK; Chi, KN; Chin, J; Ellard, SL; Hotte, SJ; Klotz, L; Kollmannsberger, C; Mukherjee, SD | 1 |
| Carducci, MA; Chi, KN; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Kavsak, P; Kollmannsberger, CK; Mukherjee, SD; Siu, LL; Smith, DC; Spreafico, A; Sridhar, SS; Sukhai, MA; Takebe, N; Wang, L; Wong, TS | 1 |
| Anand, A; Carver, B; Heller, G; Larson, SM; Morris, MJ; Rathkopf, DE; Rosen, N; Scher, HI; Shaffer, DR; Slovin, SF | 1 |
| Ahmed, RS; Gururajan, M; Karrison, T; O'Donnell, PH; Posadas, EM; Shen, J; Sievert, M; Stadler, WM; Szmulewitz, RZ; Wade, JL | 1 |
| Biordi, L; Festuccia, C; Ficorella, C; Gravina, GL; Jannini, EA; Marampon, F; Motta, M; Piccolella, M; Tombolini, V | 1 |
| Etienne-Grimaldi, MC; Fischel, JL; Lo Nigro, C; Merlano, M; Milano, G; Monteverde, M; Tonissi, F | 1 |
6 trial(s) available for quinazolines and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Indoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Treatment Outcome | 2014 |
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Piperidines; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Collagen Type I; Dasatinib; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mutation; Peptides; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sequence Analysis, DNA; src-Family Kinases; Taxoids; Thiazoles; Treatment Outcome | 2014 |
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Everolimus; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Receptors, Androgen; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Antineoplastic Agents; Benzodioxoles; Chicago; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quinazolines | 2016 |
3 other study(ies) available for quinazolines and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
Topics: Androgens; Calpain; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Quinazolines; Receptors, Androgen; Signal Transduction; Taxoids | 2017 |
Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial Cells; Erlotinib Hydrochloride; Humans; Male; Mice, Nude; Morpholines; Nitriles; Orchiectomy; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Xenograft Model Antitumor Assays | 2011 |
Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Male; Piperidines; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Taxoids; Tetrazolium Salts; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |